3 documents found, page 1 of 1
Disparities in the organisation of national healthcare systems for treatment of...
Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Midtbøll Ørnbjerg, Lykke; Horák, PavelBackground: Studies on national policies for biologics are warranted. Objectives: To map and compare national healthcare set-ups for prescription, start, switch, tapering, and discontinuation of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis and axial spondyloarthritis across Europe, and assess the healthcare set-ups in relation to countries' soci...
Interchangeability of patient pain, fatigue and global scores in patients with ...
Georgiadis, Stylianos; Di Giuseppe, Daniela; Scherer, Almut; Hetland, Merete Lund; Jones, Gareth; Glintborg, Bente; Loft, Anne Gitte; Wallman, Johan KFunding Information: Open access funding provided by Copenhagen University. Open access funding provided by Copenhagen University. Open access funding provided by Copenhagen University. This work was supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Funding Information: The EuroSpA collaboration h...
Effectiveness and treatment retention of TNF inhibitors when used as monotherap...
Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, ManuelBackground: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with P...